Kogenate® FS antihemophilic factor (recombinant) approved for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults with hemophilia A- Bayer's SPINART study met its ...

Please provide your email address to receive an email when new articles are posted on . Bayer HealthCare announced the FDA expanded the approval of the company’s recombinant antihemophilic factor VIII ...

Antihemophilic Factor VIII (recombinant) 250 IU, 500 IU, 1000 IU, 2000 IU, 3000 IU; per vial; lyophilized pwd for IV infusion after reconstitution; contains sucrose; preservative-free. Dosage Required ...

The FDA has approved a new storage option for Kogenate FS (recombinant factor VIII; Bayer HealthCare). Compared with the previous three-month room temperature option, the new option allows for storage ...

Pivotal Data Show Prophylaxis Treatment with Kogenate FS Reduces the Risk of Joint Damage and Frequent Bleeds in Children with No Pre-Existing Joint Damage BERKELEY, Calif., Oct. 10 /PRNewswire/ -- ...

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--March 3, 2005--Bayer Biological Products (Bayer BP) today launched www.KogenateFS.com. The new Web site seeks to educate the hemophilia community about ...

WHIPPANY, N.J. — Bayer HealthCare on Monday announced that the Food and Drug Administration approved the company's new indication for Bayer's Kogenate FS antihemophilic factor VIII (recombinant) for ...

Medical conference in Dubai serves as launch event as Bayer boosts its regional presence through proven antihemophilic factor product Dubai, Saudi Arabia November 12, 2006 -- Bayer HealthCare ...

February 21, 2007 — The European Commission (EC) has granted conditional approval for darunavir ethanolate, allowing its use with ritonavir and other antiretroviral drugs in the treatment of ...

Bayer is scrambling to get its hands on nearly 1,000 vials of one of its top-selling drugs after a labeling mishap led to them being filled with the wrong hemophilia medicines. The German drugmaker is ...

Bayer HealthCare announced today that the U.S. Food and Drug Administration (FDA) has approved a new indication for Bayer's Kogenate® FS antihemophilic factor VIII (recombinant), for routine ...

BERKELEY, Calif., Oct 10, 2008 /PRNewswire via COMTEX/ -- Pivotal Data Show Prophylaxis Treatment with Kogenate FS Reduces the Risk of Joint Damage and Frequent Bleeds in Children with No Pre-Existing ...